OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Clinical development and potential of photothermal and photodynamic therapies for cancer	1629
Broadening horizons: the role of ferroptosis in cancer	1210
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	813
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors	678
PD-L1 as a biomarker of response to immune-checkpoint inhibitors	643
Immunotherapies for hepatocellular carcinoma	638
Liquid biopsy enters the clinic — implementation issues and future challenges	600
Exploring the NK cell platform for cancer immunotherapy	594
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities	569
Unlocking the potential of antibody–drug conjugates for cancer therapy	502
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	475
Clinical and therapeutic relevance of cancer-associated fibroblasts	425
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	416
TGFβ biology in cancer progression and immunotherapy	409
The emerging roles of circRNAs in cancer and oncology	387
Roles and mechanisms of alternative splicing in cancer — implications for care	379
Immune-checkpoint inhibitors: long-term implications of toxicity	360
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	347
Advancing therapy for osteosarcoma	322
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	313
Harnessing cytokines and chemokines for cancer therapy	306
T cell-engaging therapies — BiTEs and beyond	291
The SWI/SNF complex in cancer — biology, biomarkers and therapy	287
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic	281
Rising incidence of early-onset colorectal cancer — a call to action	273

The adenosine pathway in immuno-oncology	265
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	250
Clinical relevance of tumour-associated macrophages	250
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	237
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	225
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives	217
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper	210
Nasopharyngeal carcinoma: an evolving paradigm	207
Intratumoural administration and tumour tissue targeting of cancer immunotherapies	203
Understanding and overcoming resistance to PARP inhibitors in cancer therapy	199
Clinical implications of T cell exhaustion for cancer immunotherapy	189
Therapeutic targeting of the hypoxic tumour microenvironment	188
Moving towards personalized treatments of immune-related adverse events	187
Targeting drugs to tumours using cell membrane-coated nanoparticles	187
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	183
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma	172
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	170
Personalized early detection and prevention of breast cancer: ENVISION consensus statement	168
Artificial intelligence in radiation oncology	164
Tumour budding in solid cancers	161
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	159
MET-dependent solid tumours — molecular diagnosis and targeted therapy	158
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	156
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer	155
CAR T cell therapies for patients with multiple myeloma	153
The implications of IDH mutations for cancer development and therapy	152
Senescence and cancer — role and therapeutic opportunities	150
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC	147
Is early-onset cancer an emerging global epidemic? Current evidence and future implications	139
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy	136
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	136
Towards precision medicine for AML	136
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	136
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	136
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	131
Immunogenicity of CAR T cells in cancer therapy	130
The current state of the art and future trends in RAS-targeted cancer therapies	129
Long-term outcomes following CAR T cell therapy: what we know so far	129
ROS1-dependent cancers — biology, diagnostics and therapeutics	124
Fundamentals and developments in fluorescence-guided cancer surgery	122
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire	122
The emerging role of photoacoustic imaging in clinical oncology	122
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	113
The blood–tumour barrier in cancer biology and therapy	113
The nuclear export protein XPO1 — from biology to targeted therapy	111
Tumour burden and efficacy of immune-checkpoint inhibitors	111
Precision oncology in metastatic colorectal cancer — from biology to medicine	110
Integrating evolutionary dynamics into cancer therapy	108
Protein degraders enter the clinic — a new approach to cancer therapy	108
Radiotheranostics in oncology: current challenges and emerging opportunities	99

Circulating tumour DNA — looking beyond the blood	98
Advancing therapy for neuroblastoma	98
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	97
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	96
Novel approaches to target the microenvironment of bone metastasis	96
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice	94
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer	92
Therapy with oncolytic viruses: progress and challenges	88
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours	81
The emerging roles of γδ T cells in cancer immunotherapy	79
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention	78
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD	78
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	77
Provision of cancer care during the COVID-19 pandemic	73
Towards clinical translation of FLASH radiotherapy	72
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide	70
COVID-19 and cancer: what we know so far	67
Beneficial autoimmunity improves cancer prognosis	63
Thermal immuno-nanomedicine in cancer	62
Progress in refining the clinical management of cancer of unknown primary in the molecular era	61
The global burden of lung cancer: current status and future trends	61
Histology-agnostic drug development — considering issues beyond the tissue	60
Neoadjuvant therapy for pancreatic cancer	60
Consequences of COVID-19 for cancer care — a CRUK perspective	59
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine	57
Humanized mouse models for immuno-oncology research	57
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy	56
The multiple roles of LDH in cancer	55
Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy	55
Gut microbiota in colorectal cancer development and therapy	53
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm	53
Older adults with cancer and their caregivers — current landscape and future directions for clinical care	51
Integrated MRI-guided radiotherapy — opportunities and challenges	48
The immune landscape of common CNS malignancies: implications for immunotherapy	48
New treatment strategies for advanced-stage gastrointestinal stromal tumours	43
Harnessing big data to characterize immune-related adverse events	43
Criteria for the translation of radiomics into clinically useful tests	42
Informative censoring — a neglected cause of bias in oncology trials	42
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management	41
Advances in the clinical management of uveal melanoma	41
The oligometastatic spectrum in the era of improved detection and modern systemic therapy	39
Predicting tumour radiosensitivity to deliver precision radiotherapy	39
Emerging evidence for adapting radiotherapy to immunotherapy	37
The roles and implications of RNA m6A modification in cancer	36
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells	36
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice	35
Towards precision oncology with patient-derived xenografts	34
Circulating tumour cells for early detection of clinically relevant cancer	34
Advancing CAR T cell therapy through the use of multidimensional omics data	33
Treatment-free remission in patients with chronic myeloid leukaemia	33
Liquid biopsy for early stage lung cancer moves ever closer	32
Systemic therapy for early-stage breast cancer: learning from the past to build the future	32
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer	31
The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment	29
COVID-19 and cancer: do we really know what we think we know?	29
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	29
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	28
The clinical development of antibody–drug conjugates — lessons from leukaemia	28